Goldman Sachs keeps Neutral on Pfizer, citing unclear product growth plans and focus on M&A amid changing market valuations ...

Nevertheless, Albert Bourla has been lobbying the U.S. government—as high as President Donald Trump himself—to skip the ...

Pfizer's CEO said tariff uncertainty is hindering the company from making big investments in the US.Albery Bourla said there ...

For years, Pfizer was the only drugmaker with treatments for the disease, called ATTR-CM, but BridgeBio’s CEO said in an ...

CEO Albert Bourla is waiting for the US government to finalize its decision on whether to place a 25% tariff on ...

Diane Brady talks to Pfizer CEO Albert Bourla about defending science amid a backdrop of political threats. The big story: ...

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump's planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and ...

Pfizer CEO says tariffs are discouraging the company from investing in the US. Pfizer's full-year guidance does not factor in ...

Pfizer’s R&D organization has been in flux for almost two years now, since the $43 billion acquisition of ADC specialist ...

Pfizer ( PFE) reported mixed first quarter earnings Tuesday, as the company struggles to gain investor interest in its ...